RNF8 and cancer: To investigate the possibility that RNF8 increases lenvatinib efficiency, we first detected lenvatinib sensitivity in cancer cell lines and discovered that lenvatinib killed Huh7 cells easily, whereas HCCLM3, HepG2 and SNU387 cells all seemed to be resistant to lenvatinib (Supplementary Figure S4).